GlassScriptPhysician profile
Bapineedu Gondi
NPI 1649295056
$4,797.90
in general payments reported to CMS, 2019-2025
33 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.30 · 2020: $29.67 · 2021: $836 · 2022: $887 · 2023: $1,231 · 2024: $1,200 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $455.06 | 2021-2024 | Xarelto |
| Abbott Laboratories | $447.29 | 2022-2025 | Mitraclip |
| Boston Scientific Corporation | $441.47 | 2021-2024 | Watchman Flx, Watchman Access System |
| Inari Medical, INC. | $342.24 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $315.63 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $291.11 | 2022-2024 | Azure Xt Dr Mri Surescan, Corevalve Evolut R |
| Pfizer INC. | $284.60 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $261.41 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $246.38 | 2021-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $202.80 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $171.73 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $149.92 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.35 | 2019-2025 | Jardiance |
| Philips North America LLC | $116.90 | 2022-2024 | (Ck4) Mcot |
| Novartis Pharmaceuticals Corporation | $105.82 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $83.04 | 2024-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $82.35 | 2021 | |
| Alnylam Pharmaceuticals INC. | $71.87 | 2024-2025 | Onpattro |
| Novo Nordisk INC | $69.28 | 2025 | Ozempic |
| Acist Medical Systems, INC. | $64.91 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.12 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $57.03 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $48.28 | 2023-2024 | |
| Chiesi USA, INC. | $46.18 | 2024-2025 | Juxtapid, Kengreal |
| Lexicon Pharmaceuticals, INC. | $43.35 | 2024 | |
| Atricure, INC. | $32.27 | 2023 | |
| Cardiva Medical, INC. | $30.99 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic Vascular, INC. | $29.05 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $24.59 | 2021-2023 | Arcalyst |
| Abiomed | $22.66 | 2025 | |
| Heartflow, INC. | $18.82 | 2025 | |
| United Therapeutics Corporation | $16.39 | 2024 | Tyvaso |
| Astellas Pharma US INC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bapineedu Gondi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.